杏吧原创

Universal cancer marker shows new treatment options

The discovery of a marker that highlights a wide range of cancers could give surgeons a "dotted line" to cut out tumours

A single screening method that can force a wide range of cancers to reveal themselves has been discovered. The universal cancer marker could help doctors find and treat tumours, and provide surgeons with a 鈥渄otted line鈥 to cut them out.

The key to the technique is the receptor for follicle-stimulating hormone (FSH). This receptor 鈥 typically involved in controlling women鈥檚 reproductive cycles 鈥 appears . So at Mount Sinai School of Medicine in New York and colleagues looked for it in 1336 human tumour samples, including prostate, breast, lung and liver cancers.

The group applied colour-labelled antibodies for the FSH receptor to the samples. They found that in every sample, the antibodies bound to blood vessels around the periphery of the tumour.

Radu doesn鈥檛 yet know why tumour blood vessels express the receptor, though he thinks it might play a role in the formation of new vessels.

One-stop screening

The marker could be useful in pinpointing and treating tumours, says Radu. Currently, different imaging techniques are used to identify different types of tumour. 鈥淯sing this marker, we can use one imaging technique for the whole body,鈥 says Radu. He hopes broader screening will enable earlier detection of secondary tumours.

at Barts and The London School of Medicine and Dentistry鈥檚 Institute of Cancer agrees: 鈥淚t鈥檚 certainly a good marker, and could be especially useful in surgery, which is a bit hit-and-miss at the moment,鈥 she says. Using colour-labelled antibodies to highlight the edges of a tumour could enable surgeons to 鈥渃ut along the dotted line鈥.

Additionally, by attaching a cancer drug to an FSH receptor antibody, 鈥渨e have the potential to target therapy exclusively to the tumour鈥, says Radu.

Drugs that inhibit the FSH receptor are already in development as potential contraceptives, says Radu. He hopes that some might be trialled as anti-cancer drugs in the future.

Journal reference: , vol聽363, p聽1621

Topics: Cancer